




Mouse IgG_{2c} Isotype Control

Cat. No.	Format	Size
0122-01	Purified (UNLB)	1.0 mg
0122-08	Biotin (BIOT)	0.5 mg
0122-14	Low Endotoxin, Azide-Free (LE/AF)	0.5 mg



ELISA plate was coated with serially diluted Mouse IgG_{2c}-UNLB (SB Cat. No. 0122-01). Immunoglobulin was detected with Goat Anti-Mouse IgG₁, Human ads-BIOT (SB Cat. No. 1070-08), Goat Anti-Mouse IgG_{2c}, Human ads-BIOT (SB Cat. No. 1079-08), Goat Anti-Mouse IgG_{2b}, Human ads-BIOT (SB Cat. No. 1090-08), Goat Anti-Mouse IgG₃, Human ads-BIOT (SB Cat. No. 1100-08), Goat Anti-Mouse IgA-BIOT (SB Cat. No. 1040-08), and Goat Anti-Mouse IgM, Human ads-BIOT (SB Cat. No. 1020-08) followed by Streptavidin-HRP (SB Cat. No. 7100-05) and quantified.

Overview

Clone	6.3
Isotype	Mouse (C57BL/6) IgG _{2c}
Specificity	Unknown

Applications

FC – Quality tested
 ELISA – Quality tested ¹⁻⁷

Working Dilutions

Flow Cytometry	BIOT conjugate For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL	≤ 1 µg/10 ⁶ cells
ELISA	Purified (UNLB) antibody	≤ 1 µg/mL
Other Applications	Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.	

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) antibody is supplied as 1.0 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The low endotoxin, azide-free (LE/AF) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of PBS. Contains no preservative; handle under aseptic conditions. Store at 2-8°C or aliquot into smaller volumes and store at -20°C. Avoid multiple freeze / thaw cycles.
- Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

References

1. Haas KM, Watanabe R, Matsushita T, Nakashima H, Ishiura N, Okochi H, et al. Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F₁ mice. *J Immunol.* 2010;184:4789-800. (ELISA)
2. Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, Weber C, et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. *EMBO Mol Med.* 2012;4:1072-86. (ELISA)
3. Allan RS, Zueva E, Cammas F, Schreiber HA, Masson V, Belz GT, et al. An epigenetic silencing pathway controlling T helper 2 cell lineage commitment. *Nature.* 2012;487:249-53. (ELISA)
4. Donius LR, Handy JM, Weis JJ, Weis JH. Optimal germinal center B cell activation and T-dependent antibody responses require expression of the mouse complement receptor Cr1. *J Immunol.* 2013;191:434-47. (ELISA)
5. Vogelzang A, McGuire HM, Liu SM, Gloss B, Mercado K, Earls P, et al. IL-21 contributes to fatal inflammatory disease in the absence of Foxp3⁺ T regulatory cells. *J Immunol.* 2014;192:1404-14. (ELISA)
6. Halemano K, Guo K, Heilman KJ, Barrett BS, Smith DS, Hasenkrug KJ, et al. Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection. *Proc Natl Acad Sci USA.* 2014;111:7759-64. (ELISA)
7. Pioli PD, Chen X, Weis JJ, Weis JH. Fatal autoimmunity results from the conditional deletion of Snai2 and Snai3. *Cell Immunol.* 2015;295:1-18. (ELISA)

TB0122
07-Oct-21